The Next Phase Of The Obesity Drug Race
The obesity drug market is rapidly evolving beyond Wegovy and Zepbound, with new pills, triple-agonist drugs, and alternative mechanisms entering clinical pipelines. Lilly's experimental Retatrutide showed unprecedented 28% average body weight loss, the highest ever recorded for a drug. Competition is intensifying across weight loss, tolerability, and dosing convenience dimensions.
Summary
The video report covers the current state and near-future pipeline of obesity medications, filmed at the American Diabetes Association's premier obesity conference. Five years after the FDA approved Novo Nordisk's GLP-1 shot Wegovy, both Novo and Eli Lilly have begun rolling out oral pill versions of their treatments, signaling a new competitive phase in the obesity drug race.
Structure Therapeutics shared Phase 2 data showing its small-molecule GLP-1 pill achieved roughly 16% body weight loss — comparable to Lilly's pill — with the added advantage of being easier to manufacture and take. CEO Ray Stevens expressed confidence that patient-driven competition will sustain market room for new entrants, positioning Structure to capture second place behind Lilly's Orforglipron.
The headline data of the conference came from Lilly's experimental triple-agonist drug Retatrutide, which targets three hormone receptors: GLP-1, GIP, and glucagon. At the highest dose, participants lost an average of 28% of body weight, with nearly half losing more than 30% — a threshold associated with bariatric surgery outcomes. Lilly acknowledged this drug would likely target patients with BMI over 40 rather than serve as a broad-market replacement for Zepbound.
Novo's CEO Mike Doustdar reframed the long-term vision for obesity treatment, arguing that obesity will become as differentiated as mental health treatment — encompassing many distinct conditions with tailored medications within the broader cardiometabolic space. Meanwhile, Zealand Pharma and Roche are pursuing a different angle with Petrelintide, an amylin analog that achieved 11% weight loss but with significantly better tolerability, particularly around vomiting. Zealand's CEO believes its superior side-effect profile could trigger an 'iPhone moment' in the market.
Finally, Pfizer and Amgen are competing on dosing convenience. Amgen is testing monthly and quarterly dosing of its experimental drug Maritide, arguing that less frequent injections could reduce patient dropout by lowering the burden of weekly or daily medication schedules. With dozens of drugs potentially launching by 2029, the obesity treatment landscape is set for significant diversification across efficacy, tolerability, and convenience.
Key Insights
- Lilly's experimental Retatrutide produced an average 28% body weight loss at the highest dose, with nearly half of participants losing more than 30% — a level associated with bariatric surgery — making it the most weight loss ever recorded from a drug to date.
- Novo CEO Mike Doustdar argued that obesity will not remain a single monolithic condition but will become as differentiated as mental health treatment, with distinct medications for distinct conditions under the broader cardiometabolic umbrella.
- Structure Therapeutics CEO Ray Stevens said the company is specifically targeting the second market position behind Lilly's Orforglipron, betting that competition among pills ultimately benefits patients and sustains room for new entrants.
- Zealand Pharma's CEO claimed that Petrelintide's superior tolerability — especially reduced vomiting compared to GLP-1 drugs — could trigger an 'iPhone moment,' causing patients to actively queue for the new modality rather than stay on existing treatments.
- Amgen argued that monthly or quarterly dosing of its experimental drug Maritide could meaningfully reduce patient dropout, framing weekly injections and even daily pills as burdensome reminders of disease that disadvantage competing drugs.
Topics
Full transcript available for MurmurCast members
Sign Up to Access